Fast, flexible space allows clinical trials to start when needed. A trial can become operational, pivot or scale without traditional capital building expenditures
The company will manufacture a cancer immunotherapy product from 2022
The partnership will help advance GreenLight's messenger RNA Covid-19 vaccine candidate
First anticipated spinout from the alliance, Circle Therapeutics, to develop novel muscle stem cell therapies for a variety of skeletal muscle disorders
This is Enzene Biosciences third biosimilar to be approved
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
Subscribe To Our Newsletter & Stay Updated
